Boston Scientific (NYSE:BSX) Price Target Increased to $52.00 by Analysts at Cowen – Slater Sentinel

Boston Scientific (NYSE:BSX) had its price target hoisted by stock analysts at Cowen from $47.00 to $52.00 in a research report issued to clients and investors on Monday, December 30th, Marketbeat Ratings reports. The brokerage presently has an outperform rating on the medical equipment providers stock. Cowens target price points to a potential upside of 20.34% from the companys current price.

Several other analysts also recently weighed in on BSX. Needham & Company LLC downgraded Boston Scientific from a strong-buy rating to a buy rating and set a $53.00 target price for the company. in a research report on Thursday, December 19th. ValuEngine lowered Boston Scientific from a buy rating to a hold rating in a research note on Tuesday, November 19th. Raymond James cut their target price on Boston Scientific from $50.00 to $48.00 and set a strong-buy rating on the stock in a research note on Monday, October 14th. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $50.00 to $55.00 and gave the company an overweight rating in a research note on Friday, December 20th. Finally, Guggenheim set a $53.00 target price on Boston Scientific and gave the company a buy rating in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the companys stock. The company presently has a consensus rating of Buy and a consensus price target of $48.62.

Shares of NYSE BSX traded down $0.36 during midday trading on Monday, hitting $43.21. 4,021,143 shares of the companys stock traded hands, compared to its average volume of 8,540,834. The firm has a fifty day moving average of $44.74 and a 200 day moving average of $42.46. The stock has a market capitalization of $61.40 billion, a price-to-earnings ratio of 56.12, a price-to-earnings-growth ratio of 2.15 and a beta of 0.78. Boston Scientific has a 1 year low of $34.35 and a 1 year high of $46.62. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.77 and a current ratio of 1.14.

In other Boston Scientific news, EVP David A. Pierce sold 5,000 shares of the companys stock in a transaction on Friday, November 1st. The stock was sold at an average price of $42.05, for a total value of $210,250.00. Following the completion of the sale, the executive vice president now directly owns 29,201 shares in the company, valued at approximately $1,227,902.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Arthur C. Butcher sold 1,104 shares of the companys stock in a transaction on Friday, November 8th. The shares were sold at an average price of $40.75, for a total value of $44,988.00. The disclosure for this sale can be found here. Insiders have sold 218,828 shares of company stock valued at $9,695,889 over the last quarter. 0.66% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Boston Scientific by 2.2% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,654,915 shares of the medical equipment providers stock valued at $243,049,000 after acquiring an additional 119,294 shares during the last quarter. North Star Investment Management Corp. acquired a new stake in Boston Scientific during the 3rd quarter worth approximately $89,000. MidWestOne Financial Group Inc. acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $444,000. BB&T Securities LLC lifted its position in Boston Scientific by 39.3% during the 3rd quarter. BB&T Securities LLC now owns 30,183 shares of the medical equipment providers stock worth $1,233,000 after acquiring an additional 8,508 shares during the period. Finally, Barings LLC lifted its position in Boston Scientific by 31.1% during the 2nd quarter. Barings LLC now owns 86,970 shares of the medical equipment providers stock worth $3,738,000 after acquiring an additional 20,612 shares during the period. Institutional investors own 91.11% of the companys stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: Trade War

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Boston Scientific (NYSE:BSX) Price Target Increased to $52.00 by Analysts at Cowen - Slater Sentinel